NCT04023903已完成1 期
A Clinical Pharmacology Study of RTA 402 (Investigation of the Effect of Food on the Pharmacokinetics of RTA 402 Capsules in Japanese Healthy Adults and Comparison of the Pharmacokinetics With Those in Caucasian Healthy Adults)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
Food effect part:
To investigate the effect of food on the pharmacokinetics of RTA 402 and evaluate the safety of RTA 402 in Japanese healthy male adults, using the capsule formulations.
Caucasian subject part:
To investigate the pharmacokinetics of a single dose of RTA 402 administered in the fasted state and compare the pharmacokinetics with those observed in Japanese healthy male adults in the food effect part
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written voluntary informed consent to participate in the study; 2) [Food Effect Part] Japanese men 20 to <40 years of age at informed consent; [Caucasian Subject Part] Caucasian men 20 to <40 years of age at informed consent; 3) BMI 18.5 kg/m2 to <25.0 kg/m2 at screening
排除标准
- •Presence of any disease requiring treatment;
- •History of heart failure (e.g., history of diagnosis of congestive heart failure categorized as Class III or IV of the New York Heart Association (NYHA) Functional Classification or history of hospitalization due to heart failure);
- •Alcoholism or drug addiction, or any positive result on drug abuse testing;
- •History of or current drug allergy;
- •Any positive result on infectious disease testing. Individuals who are positive for active antibodies produced by hepatitis B vaccination and are not infected with hepatitis B virus at screening can be enrolled in the study;
研究组 & 干预措施
RTA 402 5mg 3cap at fasting
Experimental
干预措施: Bardoxolone methyl (Drug)
RTA 402 5mg 3cap after meal
Experimental
干预措施: Bardoxolone methyl (Drug)
结局指标
主要结局
Cmax
时间窗: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours
AUC0-t
时间窗: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours
次要结局
- tmax(Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours)
- AUC0-∞(Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours)
- t1/2(Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours)
- MRT(Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours)
- kel(Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy AdultsHealthy subjectJPRN-jRCT2080224786Kyowa Kirin Co., Ltd.64
已完成
1 期
A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941HealthyPharmacokinetics of ASP1941NCT01674777Astellas Pharma Inc30
已完成
1 期
The Effect of Food on the Pharmacokinetics of BN104 TabletsHealth SubjectsNCT06724549BioNova Pharmaceuticals (Shanghai) LTD.16
已完成
1 期
The Effect of Food on the Pharmacokinetic Characteristics of CKD-501HealthyNCT01071720Chong Kun Dang Pharmaceutical24
已完成
1 期
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy VolunteersHealthyNCT02222168Boehringer Ingelheim18